Both domestic and international guidelines recommend PD-1 inhibitors alone or in combination with chemotherapy as a first-line treatment for patients with non-small cell lung cancer (NSCLC) with negative driver gene mutations, PD-L1 high expression (TPS ≥ 50%), or PD-L1 low expression (1% ≤ TPS < 50%) (3, 22, 23). This evidence concerns the gene CD274 and non-small cell lung carcinoma.